Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.

Zhang D, Ai J, Liang Z, Zhu W, Peng X, Chen X, Ji Y, Jiang H, Luo C, Geng M, Liu H.

Bioorg Med Chem Lett. 2013 Apr 15;23(8):2408-13. doi: 10.1016/j.bmcl.2013.02.037. Epub 2013 Feb 14.

PMID:
23474386
2.

Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.

Zhang W, Ai J, Shi D, Peng X, Ji Y, Liu J, Geng M, Li Y.

Molecules. 2014 Feb 24;19(2):2655-73. doi: 10.3390/molecules19022655.

3.

Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.

She N, Zhuo L, Jiang W, Zhu X, Wang J, Ming Z, Zhao X, Cong X, Huang W.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3351-5. doi: 10.1016/j.bmcl.2014.05.097. Epub 2014 Jun 6.

PMID:
24951334
4.

New aminopyrimidine derivatives as inhibitors of the TAM family.

Traoré T, Cavagnino A, Saettel N, Radvanyi F, Piguel S, Bernard-Pierrot I, Stoven V, Legraverend M.

Eur J Med Chem. 2013;70:789-801. doi: 10.1016/j.ejmech.2013.10.037. Epub 2013 Oct 22.

PMID:
24239626
5.

Discovery of novel type II c-Met inhibitors based on BMS-777607.

Zhang W, Ai J, Shi D, Peng X, Ji Y, Liu J, Geng M, Li Y.

Eur J Med Chem. 2014 Jun 10;80:254-66. doi: 10.1016/j.ejmech.2014.04.056. Epub 2014 Apr 21.

PMID:
24792774
6.

Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.

Chen D, Wang Y, Ma Y, Xiong B, Ai J, Chen Y, Geng M, Shen J.

ChemMedChem. 2012 Jun;7(6):1057-70. doi: 10.1002/cmdc.201200120. Epub 2012 May 13.

PMID:
22581753
7.

Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.

Chun K, Park JS, Lee HC, Kim YH, Ye IH, Kim KJ, Ku IW, Noh MY, Cho GW, Kim H, Kim SH, Kim J.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3983-7. doi: 10.1016/j.bmcl.2013.03.119. Epub 2013 Apr 4.

PMID:
23683591
8.

Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.

Chand K, Prasad S, Tiwari RK, Shirazi AN, Kumar S, Parang K, Sharma SK.

Bioorg Chem. 2014 Apr;53:75-82. doi: 10.1016/j.bioorg.2014.02.001. Epub 2014 Feb 17.

PMID:
24632506
9.

Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.

Ye L, Ou X, Tian Y, Yu B, Luo Y, Feng B, Lin H, Zhang J, Wu S.

Eur J Med Chem. 2013 Jul;65:112-8. doi: 10.1016/j.ejmech.2013.04.004. Epub 2013 Apr 29.

PMID:
23702473
10.

Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.

Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, Gong P.

Bioorg Med Chem. 2013 Jun 1;21(11):2843-55. doi: 10.1016/j.bmc.2013.04.013. Epub 2013 Apr 16.

PMID:
23628470
11.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Zhang D, Ai J, Liang Z, Li C, Peng X, Ji Y, Jiang H, Geng M, Luo C, Liu H.

Bioorg Med Chem. 2012 Sep 1;20(17):5169-80. doi: 10.1016/j.bmc.2012.07.007. Epub 2012 Jul 16.

PMID:
22863529
12.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.

J Med Chem. 2008 Sep 25;51(18):5766-79. doi: 10.1021/jm8006189.

PMID:
18763753
13.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4089-93. doi: 10.1016/j.bmcl.2012.04.072. Epub 2012 Apr 25.

PMID:
22595176
14.

Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.

Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM.

Bioorg Med Chem Lett. 2010 May 1;20(9):2998-3002. doi: 10.1016/j.bmcl.2010.01.042. Epub 2010 Jan 20.

PMID:
20382527
15.

Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors.

Song P, Peng P, Han M, Cao X, Ma X, Liu T, Zhou Y, Hu Y.

Bioorg Med Chem. 2014 Sep 1;22(17):4882-92. doi: 10.1016/j.bmc.2014.06.044. Epub 2014 Jun 28.

PMID:
25042558
16.

Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.

Xing W, Ai J, Jin S, Shi Z, Peng X, Wang L, Ji Y, Lu D, Liu Y, Geng M, Hu Y.

Eur J Med Chem. 2015 May 5;95:302-12. doi: 10.1016/j.ejmech.2015.03.041. Epub 2015 Mar 21.

PMID:
25827399
17.

Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.

Liu Z, Wang R, Guo R, Hu J, Li R, Zhao Y, Gong P.

Bioorg Med Chem. 2014 Jul 15;22(14):3642-53. doi: 10.1016/j.bmc.2014.05.013. Epub 2014 May 17.

PMID:
24882675
18.

Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.

Northrup AB, Katcher MH, Altman MD, Chenard M, Daniels MH, Deshmukh SV, Falcone D, Guerin DJ, Hatch H, Li C, Lu W, Lutterbach B, Allison TJ, Patel SB, Reilly JF, Reutershan M, Rickert KW, Rosenstein C, Soisson SM, Szewczak AA, Walker D, Wilson K, Young JR, Pan BS, Dinsmore CJ.

J Med Chem. 2013 Mar 28;56(6):2294-310. doi: 10.1021/jm301619u. Epub 2013 Mar 18.

PMID:
23379595
19.

Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.

Abbas HA, Al-Marhabi AR, Eissa SI, Ammar YA.

Bioorg Med Chem. 2015 Oct 15;23(20):6560-72. doi: 10.1016/j.bmc.2015.09.023. Epub 2015 Sep 15.

PMID:
26420384
20.

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.

Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J, Le P, Jalaie M, Goetz GH, Ryan K, Grodsky N, Deng YL, Parker M, Timofeevski S, Murray BW, Yamazaki S, Aguirre S, Li Q, Zou H, Christensen J.

J Med Chem. 2012 Sep 27;55(18):8091-109. Epub 2012 Sep 10. Erratum in: J Med Chem. 2012 Nov 26;55(22):10314.

PMID:
22924734
Items per page

Supplemental Content

Write to the Help Desk